IMMUTEP LIMITED - AMER

Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

23 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Publication of Abstracts at ESMO Congress 2023

16 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

03 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

21 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep to Participate in September Investor Conferences

05 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Immutep Receives Positive Scientific Advice from European Medicines Agency

01 Aug 2023 08:00:02 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q4 FY23

31 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

31 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

28 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

27 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Completes A$80 Million Capital Raise

27 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

20 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep to Participate at the Jefferies Healthcare Conference

07 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

05 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

02 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

29 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

26 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

25 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

17 May 2023 08:00:00 By Nasdaq GlobeNewswire